Latest Regulatory News

Beam Dental Bidco Pty Ltd has extended its off-market takeover offer for Pacific Smiles Group Limited, pushing the closing date to January 30, 2025. This extension signals ongoing negotiations and a potentially protracted acquisition process.

Artrya Limited has responded to an ASX price query following a notable surge in its share price, confirming no undisclosed information and adherence to continuous disclosure rules.

Visioneering Technologies reports promising interim results from its PROTECT trial, showing significant control of myopia progression in children using NaturalVue® Multifocal lenses.

Memphasys Limited has secured a major scientific endorsement for its RoXsta™ antioxidant profiling system, positioning the technology for expanded clinical and agricultural applications.

Dimerix has reached a key milestone by enrolling the first paediatric patient aged 12-17 in its ACTION3 Phase 3 trial for DMX-200, advancing its potential treatment for childhood FSGS kidney disease.

Rio Tinto's Q4 2024 production results reflect steady operational performance with record bauxite output and significant progress on key growth projects like Oyu Tolgoi and Rincon lithium expansion.

Magnetic Resources has significantly increased the gold resource estimate at its Lady Julie Gold Project to 1.75 million ounces, advancing plans for concurrent underground mining and an expanded processing plant.

BPM Minerals reports significant progress at its Claw Gold Project, completing a third drilling phase and preparing for expanded exploration across new tenements. The company maintains a strong cash position to support its growth ambitions.

Green Critical Minerals Limited (ASX: GCM) has temporarily paused trading of its securities, signaling an impending announcement that investors should watch closely.

White Cliff Minerals has secured a crucial Class A Land Use Permit for its Rae Copper Project in Nunavut, setting the stage for maiden drilling activities to begin in March 2025. This regulatory milestone follows a positive environmental screening and signals progress in unlocking high-grade copper potential.

Orthocell Limited has reported a third consecutive quarter of record revenue, driven by strong sales growth and strategic market expansions, including a key US FDA submission for its nerve repair product Remplir™.

Latitude Group Holdings Limited has revised its distribution on Capital Notes from AUD 1.6136 to AUD 2.3052, reflecting a shift to a 0% franked component and the introduction of conduit foreign income.